Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Immune Deficiency

Interventions

BIOLOGICAL: IgPro20

Sponsor

CSL Behring